Literature DB >> 2670246

The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization.

R A Van Etten1, P Jackson, D Baltimore.   

Abstract

The subcellular localization of the mouse type IV c-abl protein was determined by indirect immunofluorescence of nontransformed NIH 3T3 fibroblasts that overexpress the protein. Unlike the viral transforming protein p160gag/v-abl, which has cytoplasmic and plasma membrane localization, a large fraction of the c-abl (IV) protein is nuclear, with the remainder in the cytoplasm and plasma membrane. Deletion of a small N-terminal regulatory region of the c-abl (IV) protein, sufficient to activate its transforming potential fully, changes the distribution of the protein from the nucleus to the cytoplasm. Mapping of an amino acid sequence responsible for the nuclear localization of the c-abl (IV) protein reveals a nuclear localization signal similar to that of SV40 large T antigen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2670246     DOI: 10.1016/0092-8674(89)90102-5

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  96 in total

1.  BCR/ABL inhibition by an escort/phosphatase fusion protein.

Authors:  Y M Lim; S Wong; G Lau; O N Witte; J Colicelli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  Multiple cDNAs encoding the esk kinase predict transmembrane and intracellular enzyme isoforms.

Authors:  E M Douville; D E Afar; B W Howell; K Letwin; L Tannock; Y Ben-David; T Pawson; J C Bell
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

3.  Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences.

Authors:  R J Matthews; D B Bowne; E Flores; M L Thomas
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

4.  Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV.

Authors:  C M Verfaillie; J B McCarthy; P B McGlave
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

5.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis.

Authors:  G Shaulsky; N Goldfinger; A Ben-Ze'ev; V Rotter
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

6.  Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins.

Authors:  Ariel R Krakowski; Julien Laboureau; Alain Mauviel; Mina J Bissell; Kunxin Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-18       Impact factor: 11.205

7.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.

Authors:  J R McWhirter; J Y Wang
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

8.  En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.

Authors:  A J Muller; A M Pendergast; K Parmar; M H Havlik; N Rosenberg; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner.

Authors:  G P Nolan; T Fujita; K Bhatia; C Huppi; H C Liou; M L Scott; D Baltimore
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

10.  Myristylation alters DNA-binding activity and transactivation of FBR (gag-fos) protein.

Authors:  N Kamata; R M Jotte; J T Holt
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.